Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.57 |
| ▸ | MEN1 | O00255 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.55 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.54 |
| ▸ | SCN1A | P35498 | 1/20 | 0.50 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.50 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.50 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.49 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | JAK1 | P23458 | 1/20 | 0.49 |
| ▸ | STS | P08842 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9382114 | 1.00 | KDM4E (0.58) | KDM4EPKMGPR119MEN1KMT2A | |
| SCHEMBL14390228 | 1.00 | KDM4E (0.58) | KDM4EPKMGPR119MEN1KMT2A | |
| SCHEMBL1912989 | 0.96 | MEN1 (0.62) | KDM4EPKMGPR119MEN1KMT2A | |
| SCHEMBL23006825 | 0.92 | USP30 (0.56) | KDM4EPKMGPR119MEN1KMT2A | |
| SCHEMBL1085625 | 0.89 | MEN1 (0.54) | KDM4EPKMGPR119MEN1KMT2A | |
| SCHEMBL25078963 | 0.88 | KDM4E (0.48) | KDM4EPKMGPR119MEN1KMT2A | |
| SCHEMBL25078966 | 0.87 | KDM4E (0.47) | KDM4EPKMGPR119MEN1KMT2A | |
| SCHEMBL23527089 | 0.85 | KDM4E (0.53) | KDM4EPKMGPR119MEN1KMT2A | |
| SCHEMBL19023294 | 0.85 | KDM4E (0.53) | KDM4EPKMGPR119MEN1KMT2A | |
| SCHEMBL23527087 | 0.85 | KDM4E (0.53) | KDM4EPKMGPR119MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449475-B2 | Tricyclic spiropiperidines or spiropyrrolidines | ASTRAZENECA AB (SE) | 2008-11-11 | — | — | US | disclosed |
| US-20050245741-A1 | Novel tricyclic spiropiperidines or spiropyrrolidines | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | US | disclosed |
| EP-0394991-B1 | 1-Azabicyclo(3.2.0)Hept-2-Ene-2-carboxylic acid compounds | FUJISAWA PHARMACEUTICAL CO (JP) | 1994-08-17 | — | — | EP | disclosed |
| US-5102877-A | Carbapenicillin antibiotics | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-04-07 | — | — | US | disclosed |
| EP-0394991-A1 | 1-Azabicyclo(3.2.0)Hept-2-Ene-2-carboxylic acid compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245741-A1 | Novel tricyclic spiropiperidines or spiropyrrolidines | REN, TACR1, AGTR1 | KDM4E 2324/4885PKM 1217/4885GPR119 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.